Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease

• Ngā kaituhi matua: Beatriz Orts (Author), Ana Gutierrez (Author), Lucía Madero (Author), Laura Sempere (Author), Ruben Frances (Author), Pedro Zapater (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Introduction: Up to 40% of patients with Crohn's disease do not respond to treatment with anti-TNF or lose response after the initial benefit. Low drug concentrations have been proposed as the main predictor of treatment failure. Our aim was to study the immunological profile and clinical evolu...